Navigation Links
Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder

Two clinical trials of the novel drug romiplostim (Nplate) show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura (ITP), a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital (MGH) investigator, in the February 2 issue of The Lancet.

Many ITP patients have had to choose between no therapy or a treatment with limited efficacy and potentially serious side effects, says David Kuter, MD, DrPhil, director of Clinical Hematology at MGH and lead author of the Lancet study. The low toxicity and high response to this drug may convert a potentially life-threatening condition to one that can be easily managed with a weekly injection.

ITP is a chronic disorder in which the immune system destroys platelets, blood cells that help prevent bleeding. While some ITP patients experience only increased bruising, others may have serious bleeding and occasionally dangerous hemorrhage. Recent investigations suggest that, in addition to the destruction of existing platelets, ITP also may be due to reduced platelet production. Currently available treatments for ITP including steroid drugs, which have significant side effects, and removal of the spleen (splenectomy) are designed to reduce platelet destruction and may be ineffective in many patients.

Thrombopoietin is the natural regulator of platelet production. Kuter was one of the original discoverers of the hormone in 1994 and has been active in developing thrombopoietic drugs ever since. Romiplostim is a unique peptibody a peptide antibody that stimulates platelet production by mimicking the action of thrombopoietin. Earlier Phase 1 and 2 trials have shown that romiplostim increases platelet production in healthy volunteers and in short-term treatment of ITP patients.

The double-blinded Phase 3 trials were conducted at 35 sites in the U.S. and Europe. One trial enrolled 63 splenectomized patients, the other included 62 patients who retained their spleens. Both groups were randomly assigned to receive either romiplostim or a placebo in weekly injections during the 24-week study period. Participants platelet levels were monitored during the trial, and dosage was adjusted to achieve a target platelet count of 50,000/ml.

Among the 42 splenectomized patients who received romiplostim, nearly 80 percent reached the target platelet count during at least four weeks of the study, and 38 percent achieved a durable response, maintaining a target platelet count during at least six of the last eight weeks of the study. In the non-splenectomized patients, 88 percent had at least four target platelet count measurements, with 61 percent achieving a durable response.

More than half the patients receiving romiplostim were able to discontinue all other ITP medications they were taking, and 35 percent reduced other therapies. While over half the participants in the placebo groups of both studies needed rescue medications to treat or prevent bleeding episodes, significantly fewer of those receiving the active medication needed such treatment.

Were seeing dramatic results for this totally new approach to treating people with ITP, Kuter says. Ive been working on the development of thrombopoietin since 1983, and its very gratifying to participate in its discovery, purification, drug development and now the studies showing its clinical effectiveness. He adds that his MGH team and other researchers are conducting other romiplostim trials and will continue to investigate the drugs usefulness for treating ITP and other conditions of reduced platelet production, such as those caused by cancer or cancer treatment.


Contact: Sue McGreevey
Massachusetts General Hospital

Related medicine news :

1. Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery
2. A New Series Is Born on Discovery Health
3. ITRAC on track and bridging gap between academic research and applied discovery
4. Discovery opens door to personalized asthma therapy
5. Linguamatics and 81qd Sign Multi-Year Collaboration in Knowledge Discovery for Product Life Cycle Management
6. Fight against hay fever and other allergies helped by new immune system discovery
7. Discovery Healths Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle
8. Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health
9. Kaiser Permanente and Discovery Health Team Up to Fight Childhood Obesity Epidemic
10. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
11. OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia
Post Your Comments:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: